Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/uj8RPPawWuc/268182.php
Saturday, 2 November 2013
The Medicines Company's EUROMAX trial of Angiox(r) (bivalirudin) in heart attack meets all prespecified endpoints
The Medicines Company (NASDAQ: MDCO) today announced results from the EUROMAX Trial, a 2,218 patient Phase IIIb randomized study of the Company's Angiox� (bivalirudin), which is marketed as Angiomax� (bivalirudin) in the US. The trial met its pre-specified primary and secondary endpoints, including statistically significant reductions in the primary composite endpoint of death and major bleeding among patients randomized to Angiox...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment